Solna, Sweden, June 28, 2013. The Affibody Holding AB’s (publ) (Affibody) AGM convened earlier today in Solna and voted in favour of the resolutions proposed at the meeting, including:
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 200 043 889. The board members and the chief executive officer were discharged from liability for the financial year 2012.
Election of Board of Directors, remuneration to the Directors and election of Auditor
The ordinary board members Håkan Åström, Björn Odlander, Mathias Uhlén, Jacob Lindberg and Jonathan Knowles were re-elected and Håkan Åström was re-elected chairman of the Board. The AGM approved the compensation to the Board in accordance with the proposal.
For full details on each proposal adopted by the AGM please refer to www.affibody.com.
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.
Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Sobi, GE, Daiichi-Sankyo, Daewoong, and Thermo Fisher.
Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor AB.
Further information can be found at: www.affibody.com